Reagents That Control Stem Cell Differentiation

Funding Type: 
Tools and Technologies I
Grant Number: 
RT1-01006
Investigator: 
ICOC Funds Committed: 
$0
oldStatus: 
Closed
Public Abstract: 
In diseases of the nervous system such as Parkinson’s disease (PD) and Lou Gehrig’s disease very specific groups of nerve cells die. At least in the case of PD, the surgical methods exist for the implantation of new cells into the area of the brain where the nerve cells are dying. However, since fetal brain cells are almost impossible to obtain, an alternative must be found. A viable and untested potential source of brain neurons are human embryonic stem (ES) cells. In order to get these cells to function in the brain, it is mandatory that the ES cells be converted to nerve cells before they can be surgically implanted. In our past work with rat and mouse stem cells we have been able to identify and purify factors that are made by nerve precursor cells that cause stem cells to become neurons. In addition, we have a very large potential source of these types of factors that is unique to our laboratory in the form of embryonic cell lines from the brain. Therefore, the goal of this proposal is to identify new factors that convert human ES cells to specific types of neurons. Because we have previously identified nerve differentiation factors from our cell lines, we are certain that there are additional molecules to be discovered. These growth and differentiation factors will be of enormous help in meeting the technical requirements for successfully using human stem cells for the treatment of chronic neurological diseases.
Statement of Benefit to California: 
Our work will benefit the State in a number of ways. 1) There could be a tremendous health benefit for individuals with diseases of the brain such as Parkinson’s and Lou Gehrig’s diseases as well as damage due to stroke or trauma. 2) Support for this work will provide current employment within the State and help educate scientists in the stem cell field. 3) The advancement of work on novel growth factors will require the collaboration with commercial (for profit) companies. Most of early stage preclinical development is done in small biotech companies, many of which are within the State. Therefore, there is an economic benefit to the State as well as a health benefit to the State and the world if some of the most debilitating human diseases could be cured.

© 2013 California Institute for Regenerative Medicine